Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation and expansion study of LOP628 in cKit-positive tumors and acute myeloid leukemia
NL-OMON42287Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LOP628 in gastrointestinal stromal tumor (GIST), small cell lung cancer (SCLC) and acute myeloid leukemia (AML), sponsored by Novartis. Primary endpoint: Incidence rate of dose-limiting toxicities. Started Dec 2014; status: active, not recruiting.
02
Drugs
LOP628
03
Conditions
gastrointestinal stromal tumor (GIST)small cell lung cancer (SCLC)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON42287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42287.